Lipase Levels and Coronavirus Disease 2019
Completed
- Conditions
- PancreatitisLipase Increased
- Interventions
- Other: Age, gender, hospitalization and mortality rates will be compared
- Registration Number
- NCT05601258
- Lead Sponsor
- Uşak University
- Brief Summary
Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common.
In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury and acute pancreatitis in the course of COVID 19 disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Not specified
- Target Recruitment
- 4000
Inclusion Criteria
- Patients with lipase levels measured during COVID-19
Exclusion Criteria
Patients with age <18 years Patients with pregnancy Patients whose lipase levels were not measured in the course of COVID-19 Patients with known solid organ malignacy Patients with known hematologic malignacy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Control Age, gender, hospitalization and mortality rates will be compared patients with normal lipase levels in the course of SARS-CoV-2 infection patients with higher lipase level Age, gender, hospitalization and mortality rates will be compared patients with higher lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
- Primary Outcome Measures
Name Time Method The frequency of lipase enzyme elevation will be compared From 31th March 2020 until 9th July 2021 The mortaliy rate will be compared From 31th March 2020 until 9th July 2021
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Cevdet Duran
🇹🇷Usak, Turkey